BioSpace News Archive

IMV Inc., is pleased to announce that Institutional Shareholder Services Inc. and Glass, Lewis & Co., LLC, have recommended that shareholders vote FOR all of the items submitted for shareholder approval at this year’s Annual and Special Meeting of Shareholders.

Humanigen, Inc., a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the company’s proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody, announced data on the first clinical use of lenzilumab in 12 COVID-19 patients.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat orphan seizure disorders, today announced that Martha Manning, Esq., has been appointed Vice President, General Counsel and Secretary. “We are thrilled to welcome Martha to our growing team at Marinus, and believe her legal experience supporting biopharma companies across all development stages will be instr

SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), , today announced that the United States Department of Defense (DoD), via the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense’s (JPEO-CBRND) Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), has increased research

Repligen Corporation (NASDAQ:RGEN) today announced the appointment of healthcare industry executive Carrie Eglinton Manner to its Board of Directors.

More Than 97% Of Notes Sought Were Tendered And Accepted Thereby Extending More Than $2.7 Billion Of Endo International plc’s Near-Term Debt Maturities

Epsilen Bio, a biotechnology company developing transformative therapies for patients affected by underserved medical conditions through stable epigenetic silencing of genes involved in pathological processes, announced the appointments of Julia Berretta, Ph.D, as Chief Executive Officer, and Mathieu Simon, M.D., as Chairman of the Board.

Oncopeptides AB announces that the full top-line results from the pivotal phase 2 HORIZON study, evaluating intravenous melflufen in combination with dexamethasone in patients with relapsed refractory multiple myeloma, have been presented at the ongoing 25th European Hematology Association meeting, EHA.

Added responsibilities underscore company’s focus on commercial growth for the IRRAflow® and Hummingbird product lines

Aridis Pharmaceuticals, Inc. announced that it has appointed Dr. Hasan Jafri as Chief Medical Officer. Dr. Jafri replaces Dr. Paul Mendelman who has been serving as the Company’s interim CMO since October, 2019 and will transition to the role of senior medical advisor to the Company.